☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Legend Biotech
Janssen and Legend Biotech Report the sBLA Submission of Carvykti (ciltacabtagene autoleucel) to the US FDA for Relapsed or Refrac...
June 7, 2023
Legend Biotech Reports NMPA’s Acceptance of NDA for Ciltacabtagene Autoleucel (Cilta-Cel) in Multiple Myeloma
January 2, 2023
Legend Biotech’s Carvykti (ciltacabtagene autoleucel) Receives the US FDA’s Approval for the Treatment of Multiple Myeloma
March 1, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.